The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials

Min, Thinzar; Bain, Steve

doi:10.1007/s13300-020-00981-0

Journal article 866 views 798 downloads

The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials

Thinzar Min, Steve Bain

Diabetes Therapy, Volume: 12, Issue: 1, Pages: 143 - 157

Swansea University Authors: Thinzar Min, Steve Bain

PDF | Version of Record

©The Author(s) 2020. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Download (379.28KB)

Check full text

DOI (Published version): 10.1007/s13300-020-00981-0

Published in:	Diabetes Therapy
ISSN:	1869-6953 1869-6961
Published:	Springer Science and Business Media LLC 2021
Online Access:	Check full text
URI:	https://cronfa.swan.ac.uk/Record/cronfa55784
Tags:	Add Tag No Tags, Be the first to tag this record!

first_indexed	2020-11-30T09:41:03Z
last_indexed	2021-05-04T03:20:42Z
id	cronfa55784
recordtype	SURis
fullrecord	<?xml version="1.0"?><rfc1807><datestamp>2021-05-03T13:11:56.8429049</datestamp><bib-version>v2</bib-version><id>55784</id><entry>2020-11-30</entry><title>The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials</title><swanseaauthors><author><sid>27cba511a4800fefddb6885ffffdb8b2</sid><firstname>Thinzar</firstname><surname>Min</surname><name>Thinzar Min</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>5399f4c6e6a70f3608a084ddb938511a</sid><ORCID>0000-0001-8519-4964</ORCID><firstname>Steve</firstname><surname>Bain</surname><name>Steve Bain</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2020-11-30</date><deptcode>BMS</deptcode><abstract/><type>Journal Article</type><journal>Diabetes Therapy</journal><volume>12</volume><journalNumber>1</journalNumber><paginationStart>143</paginationStart><paginationEnd>157</paginationEnd><publisher>Springer Science and Business Media LLC</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>1869-6953</issnPrint><issnElectronic>1869-6961</issnElectronic><keywords>Glucagon-like peptide 1; Glucose-dependent insulinotropic polypeptide; Incretin hormone; Type 2 diabetes; Tirzepatide</keywords><publishedDay>1</publishedDay><publishedMonth>1</publishedMonth><publishedYear>2021</publishedYear><publishedDate>2021-01-01</publishedDate><doi>10.1007/s13300-020-00981-0</doi><url/><notes/><college>COLLEGE NANME</college><department>Biomedical Sciences</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>BMS</DepartmentCode><institution>Swansea University</institution><apcterm/><lastEdited>2021-05-03T13:11:56.8429049</lastEdited><Created>2020-11-30T09:38:47.0969735</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Thinzar</firstname><surname>Min</surname><order>1</order></author><author><firstname>Steve</firstname><surname>Bain</surname><orcid>0000-0001-8519-4964</orcid><order>2</order></author></authors><documents><document><filename>55784__19061__77d6641fb1ae4f2fbf05e99760d8d677.pdf</filename><originalFilename>55784.pdf</originalFilename><uploaded>2021-01-14T13:21:26.4032431</uploaded><type>Output</type><contentLength>388379</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>©The Author(s) 2020. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by-nc/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling	2021-05-03T13:11:56.8429049 v2 55784 2020-11-30 The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials 27cba511a4800fefddb6885ffffdb8b2 Thinzar Min Thinzar Min true false 5399f4c6e6a70f3608a084ddb938511a 0000-0001-8519-4964 Steve Bain Steve Bain true false 2020-11-30 BMS Journal Article Diabetes Therapy 12 1 143 157 Springer Science and Business Media LLC 1869-6953 1869-6961 Glucagon-like peptide 1; Glucose-dependent insulinotropic polypeptide; Incretin hormone; Type 2 diabetes; Tirzepatide 1 1 2021 2021-01-01 10.1007/s13300-020-00981-0 COLLEGE NANME Biomedical Sciences COLLEGE CODE BMS Swansea University 2021-05-03T13:11:56.8429049 2020-11-30T09:38:47.0969735 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Thinzar Min 1 Steve Bain 0000-0001-8519-4964 2 55784__19061__77d6641fb1ae4f2fbf05e99760d8d677.pdf 55784.pdf 2021-01-14T13:21:26.4032431 Output 388379 application/pdf Version of Record true ©The Author(s) 2020. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License true eng http://creativecommons.org/licenses/by-nc/4.0/
title	The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials
spellingShingle	The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials Thinzar Min Steve Bain
title_short	The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials
title_full	The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials
title_fullStr	The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials
title_full_unstemmed	The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials
title_sort	The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials
author_id_str_mv	27cba511a4800fefddb6885ffffdb8b2 5399f4c6e6a70f3608a084ddb938511a
author_id_fullname_str_mv	27cba511a4800fefddb6885ffffdb8b2_*_Thinzar Min 5399f4c6e6a70f3608a084ddb938511a_*_Steve Bain
author	Thinzar Min Steve Bain
author2	Thinzar Min Steve Bain
format	Journal article
container_title	Diabetes Therapy
container_volume	12
container_issue	1
container_start_page	143
publishDate	2021
institution	Swansea University
issn	1869-6953 1869-6961
doi_str_mv	10.1007/s13300-020-00981-0
publisher	Springer Science and Business Media LLC
college_str	Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id	facultyofmedicinehealthandlifesciences
hierarchy_top_title	Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id	facultyofmedicinehealthandlifesciences
hierarchy_parent_title	Faculty of Medicine, Health and Life Sciences
department_str	Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
document_store_str	1
active_str	0
published_date	2021-01-01T04:10:15Z
_version_	1763753711752970240
score	11.013126

The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials

Similar Items